Loading
A phase 3 trial of Glasdegib and Azacitidine in Acute myeloid leukaemia and Leukaemia, run by Pfizer, completed.
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML is a phase 3 interventional study registered as NCT04842604 by Pfizer, with 14 participants recorded, started 2021-05-17 and reaching its primary completion in 2022-12-02. Interventions recorded: Glasdegib, Azacitidine. Conditions recorded: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia.
Linked to the drug Glasdegib because the registry names it among its interventions and Acute myeloid leukaemia and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Shares Glasdegib, Azacitidine, Pfizer (incl. Seagen), Leukaemia (all types) and the tag pipeline.
Shares Glasdegib, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Leukaemia (all types) and the tag pipeline.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Leukaemia (all types) and the tag pipeline.
Shares Azacitidine, Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.